Monoclonal antibodies in the treatment of metastatic colorectal cancer: A review

Clinical Therapeutics

Volumn 32, Issue 3, 2010, Pages 437-453

  Tol, Jolien ^a   Punt, Cornelis J A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

KRAS mutation; Metastatic colorectal cancer; Review; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; VASCULOTROPIN A; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2;

ARTERY THROMBOSIS; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG ERUPTION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; GENE MUTATION; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; INJECTION SITE REACTION; METASTASIS; MONOTHERAPY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEINURIA; REVIEW; VENOUS THROMBOEMBOLISM;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG DELIVERY SYSTEMS; HUMANS; MUTATION; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77951936254     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.03.012     Document Type: Review

References (87)

1. Weitz J, Koch M, Debus J, et al. Colorectal cancer. Lancet. 2005, 365:153-165.
2. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol. 1992, 10:896-903. Advanced Colorectal Cancer Meta-Analysis Project.
3. Díaz-Rubio E, Tabernero J, Gómez-España A, et al. Phase III study of capecitabine plus ox-aliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: Final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol. 2007, 25:4224-4230. Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.
4. Porschen R, Arkenau HT, Kubicka S, et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leuco-vorin plus oxaliplatin in metastatic colorectal cancer: A final report of the AIO Colorectal Study Group. J Clin Oncol. 2007, 25:4217-4223. AIO Colorectal Study Group.
5. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol. 2001, 19:4097-4106. Xeloda Colorectal Cancer Study Group.
6. Punt CJ New options and old dilemmas in the treatment of patients with advanced colorectal cancer. Ann Oncol. 2004, 15:1453-1459.
7. Koopman M, Punt CJ Chemotherapy, which drugs and when. Eur J Cancer. 2009, 45(Suppl 1):50-56.
8. Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, iri-notecan, and oxaliplatin in advanced colorectal cancer (CAIRO): A phase III randomised controlled trial. Lancet. 2007, 370:135-142.
9. Koopman M, Seymour MT, Punt CJ The CAIRO and FOCUS studies: Which lesson is to be learned?. Oncologist. 2009, 14:192-193. Letter.
10. Seymour MT, Maughan TS, Ledermann JA, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): A randomised controlled trial [published correction appears in Lancet. 2007;370:566]. Lancet 2007, 370:143-152. FOCUS Trial Investigators, National Cancer Research Institute Colorectal Clinical Studies GroupNational Cancer Research Institute Colorectal Clinical Studies Group.
11. Arkenau HT, Arnold D, Cassidy J, et al. Efficacy of oxaliplatin plus cape-citabine or infusional fluorouracil/ leucovorin in patients with meta-static colorectal cancer: A pooled analysis of randomized trials [published correction appears in J Clin Oncol. 2009;27:5859]. J Clin Oncol. 2008, 26:5910-5917.
12. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study. J Clin Oncol. 2007, 25:4779-4786.
13. Köhne CH, De Greve J, Hartmann JT, et al. Irinotecan combined with infusional 4-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorec-tal cancer. EORTC study 40015. Ann Oncol. 2008, 19:920-926.
14. Punt CJ, Koopman M Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer. J Clin Oncol. 2008, 26:1907-1908. Letter.
15. Cohen SJ, Cohen RB, Meropol NJ Targeting signal transduction pathways in colorectal cancer-more than skin deep. J Clin Oncol. 2005, 23:5374-5385.
16. Spano JP, Fagard R, Soria JC, et al. Epidermal growth factor receptor signaling in colorectal cancer: Pre-clinical data and therapeutic perspectives. Ann Oncol. 2005, 16:189-194.
17. Tabernero J, Rojo F, Calvo E, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everoli-mus: A phase I tumor pharmacody-namic study in patients with advanced solid tumors. J Clin Oncol. 2008, 26:1603-1610.
18. Yeh TC, Marsh V, Bernat BA, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res. 2007, 13:1576-1583.
19. Mross K, Steinbild S, Baas F, et al. Results from an in vitro and a clinical/ pharmacological phase I study with the combination irinotecan and sorafenib. Eur J Cancer. 2007, 43:55-63.
20. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008, 26:1626-1634.
21. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008, 19:508-515.
22. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in meta-static colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer. 2007, 96:1166-1169.
23. Lièvre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008, 26:374-379.
24. Ferrara N, Gerber HP, LeCouter J The biology of VEGF and its receptors. Nat Med. 2003, 9:669-676.
25. Duff SE, Jeziorska M, Rosa DD, et al. Vascular endothelial growth factors and receptors in colorectal cancer: Implications for anti-angiogenic therapy. Eur J Cancer. 2006, 42:112-117.
26. Niu G, Wright KL, Huang M, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002, 21:2000-2008.
27. Dvorak HF Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002, 20:4368-4380.
28. Des Guetz G, Uzzan B, Nicolas P, et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer. 2006, 94:1823-1832.
29. Rajaganeshan R, Prasad R, Guillou PJ, et al. The influence of invasive growth pattern and microvessel density on prognosis in colorectal cancer and colorectal liver metastases. BrJ Cancer. 2007, 96:1112-1117.
30. Jubb AM, Hurwitz HI, Bai W, et al. Impact of vascular endothelial growth factor-A expression, throm-bospondin-2 expression, and mi-crovessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol. 2006, 24:217-227.
31. Scaltriti M, Baselga J The epidermal growth factor receptor pathway: A model for targeted therapy. Clin Cancer Res. 2006, 12:5268-5272.
32. Goldstein NS, Armin M Epidermal growth factor receptor immunohis-tochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarci-noma: Implications for a standardized scoring system. Cancer. 2001, 92:1331-1346.
33. Spano JP, Lagorce C, Atlan D, et al. Impact of EGFR expression on colo-rectal cancer patient prognosis and survival. Ann Oncol. 2005, 16:102-108.
34. Zlobec I, Vuong T, Hayashi S, et al. A simple and reproducible scoring system for EGFR in colorectal cancer: Application to prognosis and prediction of response to preopera-tive brachytherapy. Br J Cancer. 2007, 96:793-800.
35. Kountourakis P, Pavlakis K, Psyrri A, et al. Clinicopathologic significance of EGFR and Her-2/neu in colorectal adenocarcinomas. Cancer J. 2006, 12:229-236.
36. Takahari D, Yamada Y, Okita NT, et al. Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer. Oncology. 2009, 76:42-48.
37. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colo-rectal cancer patients with tumors that do not express the epidermal growth factor receptor by immuno-histochemistry. J Clin Oncol. 2005, 23:1803-1810.
38. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004, 351:337-345.
39. Bibeau F, Boissière-Michot F, Sabourin JC, et al. Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray. Virchows Arch. 2006, 449:281-287.
40. Molinari F, Martin V, Saletti P, et al. Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related meta-static sites may be clinically relevant. Br J Cancer. 2009, 100:1087-1094.
41. Italiano A, Saint-Paul MC, Caroli-Bosc FX, et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: Biological and clinical implications. Ann Oncol. 2005, 16:1503-1507.
42. Viloria-Petit AM, Kerbel RS Acquired resistance to EGFR inhibitors: Mechanisms and prevention strategies. Int J Radiat Oncol Biol Phys. 2004, 58:914-926.
43. Garm Spindler KL, Pallisgaard N, Rasmussen AA, et al. The impor- tance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann Oncol. 2009, 20:879-884.
44. Loupakis F, Pollina L, Stasi I, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol. 2009, 27:2622-2629.
45. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: The multicenter "RASCAL" study. J Natl Cancer Inst. 1998, 90:675-684.
46. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007, 67:2643-2648.
47. Committee for Medicinal Products for Human Use Post-authorisation Summary of Positive Opinion for Erbitux European Medicines Agency, Accessed December 1, 2009. http://www.emea.europa.eu/pdfs/human/opinion/Erbitux_28040208en.pdf.
48. Oliveira C, Westra JL, Arango D, et al. Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet. 2004, 13:2303-2311.
49. Jimeno A, Messersmith WA, Hirsch FR, et al. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: Practical application of patient selection. J Clin Oncol. 2009, 27:1130-1136.
50. Tol J, Dijkstra JR, Vink-Börger ME, et al. High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue [published online ahead of print May 13, 2009]. J Cell Mol Med.
51. van Krieken JH, Jung A, Kirchner T, et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: Proposal for an European quality assurance program [published correction appears in Virchows Arch. 2009; 454:233-235]. Virchows Arch. 2008, 453:417-431.
52. Tol J, Nagtegaal ID, Punt CJ BRAF mutation in metastatic colorectal cancer. N EnglJMed. 2009, 361:98-99.
53. Bibeau F, Lopez-Crapez E, Di Fiore F, et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetux-imab plus irinotecan. J Clin Oncol. 2009, 27:1122-1129.
54. Zhang W, Gordon M, Schultheis AM, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing meta-static colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007, 25:3712-3718.
55. Hurwitz H, Fehrenbacher L, Novot-ny W, et al. Bevacizumab plus irino-tecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N EnglJ Med. 2004, 350:2335-2342.
56. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study. Lancet Oncol. 2005, 6:279-286.
57. Sartore-Bianchi A, Moroni M, Veronese S, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colo-rectal cancer treated with panitu-mumab. J Clin Oncol. 2007, 25:3238-3245.
58. Sartore-Bianchi A, Martini M, Moli-nari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009, 69:1851-1857.
59. Prenen H, De SJ, Jacobs B, et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res. 2009, 15:3184-3188.
60. Di Nicolantonio F, Martini M, Mo-linari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008, 26:5705-5712.
61. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol. 2005, 23:3697-3705.
62. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of ox-aliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE Study [published correction appears in J Clin Oncol. 2008;26:4697]. J Clin Oncol. 2008, 26:3523-3529.
63. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study [published corrections appear in J Clin Oncol. 2009;27:653 and J Clin Oncol. 2008;26:3110]. J Clin Oncol. 2008, 26:2013-2019.
64. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leuco-vorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007, 25:1539-1544. Eastern Cooperative Oncology Group Study E3200.
65. Saif MW, Elfiky A, Salem RR Gastrointestinal perforation due to be-vacizumab in colorectal cancer. Ann Surg Oncol. 2007, 14:1860-1869.
66. Tol J, Cats A, Mol L, et al. Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. Invest New Drugs. 2008, 26:393-397.
67. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009, 360:1408-1417.
68. Bokemeyer C, Bondarenko I, Makh-son A, et al. Fluorouracil, leucovor-in, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009, 27:663-671.
69. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: Phase III trial of cetux-imab plus irinotecan after fluoropy-rimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008, 26:2311-2319.
70. Jonker DJ, O'Callaghan CJ, Karape-tis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007, 357:2040-2048.
71. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of pani-tumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007, 25:1658-1664.
72. Saltz LB, Meropol NJ, Loehrer PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004, 22:1201-1208.
73. Peréz-Soler R, Saltz L Cutaneous adverse effects with HER1/EGFR-targeted agents: Is there a silver lining?. J Clin Oncol. 2005, 23:5235-5246.
74. Tejpar S, Piessevaux H, Claes K, et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: A prospective study. Lancet Oncol. 2007, 8:387-394.
75. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008, 359:1757-1765.
76. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009, 360:563-572.
77. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009, 27:672-680.
78. Antonacopoulou AG, Tsamandas AC, Petsas T, et al. EGFR, HER-2 and COX-2 levels in colorectal cancer. Histopathology. 2008, 53:698-706.
79. Jung YD, Mansfield PF, Akagi M, et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer. 2002, 38:1133-1140.
80. Shaheen RM, Ahmad SA, Liu W, et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer. 2001, 85:584-589.
81. Tonra JR, Deevi DS, Corcoran E, et al. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res. 2006, 12:2197-2207.
82. Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res. 2000, 6:3739-3747.
83. Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase II trial of cetux-imab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study. J Clin Oncol. 2007, 25:4557-4561.
84. Simkens L, Tol J, Koopman M, et al. Current questions in the treatment of advanced colorectal cancer: The CAIRO studies of the Dutch Colo-rectal Cancer Group. Clin Colorectal Cancer. 2008, 7:105-109.
85. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE). J Clin Oncol. 2008, 26:5326-5334.
86. Pohlmann PR, Mernaugh RL, Goff LW Chemotherapy and immuno-therapy in metastatic colorectal cancer. N Engl J Med. 2009, 360:2134. Letter.
87. Kyzas PA, Loizou KT, Ioannidis JP Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst. 2005, 97:1043-1055.